Orchard raises $150m to advance gene therapies
UK-American biotech Orchard Therapeutics has raised $150 million to fuel development of its gene therapy pipeline.
Read More
Tag: OTL-101
Orchard’s ‘bubble baby’ therapy awarded PIM status
UK regulators have awarded Orchard Therapeutics’ experimental ‘bubble baby’ disease therapy OTL-101 Promising Innovative Medicine status, pushing the drug closer to being accepted onto the Early Access to Medicines Scheme.
Read More
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
- Theolytics announces first patient dosed in the Octopod‑IP trial
- UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
